PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $16 at Needham & Company
May 14, 2021 1:51 PM EDTNeedham & Company analyst Chad Messer lowered the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) to $16.00 (from $19.00) while maintaining a Buy rating.
The analyst commenetd, "In March, PhaseBio announced enrollment in the Phase III REVERSE-IT trial was running ahead of schedule, enrolling... More



